open access
Implementation of a population-based breast cancer prevention program in Poland before, during and after the COVID-19 pandemic. Poland in comparison with other countries
Affiliations- Department of Economics of Health and Medical Law, Medical University of Warsaw, Warsaw, Poland
- School of Public Health, Centre of Postgraduate Medical Education of Warsaw, Warsaw, Poland
open access
Abstract
Introduction. Breast cancer is the most common malignant tumor in women in Poland and in the world. It accounts for about 24% of all cancer cases in Polish women. The aim of this study was to analyze the coverage of the population eligible for a population-based breast cancer prevention program in Poland before, during and after the COVID-19 pandemic, and to compare the Polish data with data from other countries around the world.
Material and methods. The study was based on epidemiological data related to the performance of mammography examinations among Polish women under the breast cancer prevention program. The results were compared with data from other countries around the world.
Results. In the years 2014–2022, a significant decrease was observed in the number of mammography examinations among Polish women under the population-based breast cancer prevention program.
Conclusions. A continuous decrease in the number of preventive examinations in Poland is related not only to the COVID-19 pandemic, but also to the discontinuation of sending paper invitations for mammography under the breast cancer prevention program.
Abstract
Introduction. Breast cancer is the most common malignant tumor in women in Poland and in the world. It accounts for about 24% of all cancer cases in Polish women. The aim of this study was to analyze the coverage of the population eligible for a population-based breast cancer prevention program in Poland before, during and after the COVID-19 pandemic, and to compare the Polish data with data from other countries around the world.
Material and methods. The study was based on epidemiological data related to the performance of mammography examinations among Polish women under the breast cancer prevention program. The results were compared with data from other countries around the world.
Results. In the years 2014–2022, a significant decrease was observed in the number of mammography examinations among Polish women under the population-based breast cancer prevention program.
Conclusions. A continuous decrease in the number of preventive examinations in Poland is related not only to the COVID-19 pandemic, but also to the discontinuation of sending paper invitations for mammography under the breast cancer prevention program.
Keywords
breast cancer; prevention; cancer
About this articleTitle
Implementation of a population-based breast cancer prevention program in Poland before, during and after the COVID-19 pandemic. Poland in comparison with other countries
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Research paper (original)
Pages
122-128
Published online
2023-05-31
Page views
1365
Article views/downloads
392
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2023;73(3):122-128.
Keywords
breast cancer
prevention
cancer
Authors
Mariola W. Borowska
Urszula Religioni
Anna Augustynowicz
References (30)- Wojciechowska U, Barańska K, Michałek I, et al. Nowotwory złośliwe w Polsce w 2020 roku. Ministerstwo Zdrowia, Warszawa 2022.
- Health at a Glance 2021. https://www.oecd.org/health/health-at-a-glance/ (15.01.2023).
- Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol. 2020; 21(9): 1165–1172.
- https://onkologia.org.pl/pl/epidemiologia/nowotwory-zlosliwe-w-polsce (15.01.2023).
- Kozierkiewicz A. Biała Księga. Zwalczanie raka jelita grubego i raka piersi w Polsce na tle wybranych krajów europejskich. Ośrodek Analiz Uniwersyteckich, Warszawa-Kraków 2011.
- Brożek I, Limon J. Poradnictwo genetyczne w dziedzicznym raku piersi. In: Jassem J, Krzakowski M. ed. Rak piersi. Praktyczny przewodnik dla lekarzy. Via Medica, Gdańsk 2009: 20–31.
- Paluch-Shimon S, Cardoso F, Sessa C, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016; 27(suppl 5): v103–v110.
- De Felice F, Marchetti C, Musella A, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol. 2015; 22(9): 2876–2880.
- Kuhl C, Schrading S, Leutner C, et al. Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. J Clin Oncol. 2005; 23(33): 8469–8476.
- Wolff A, Hammond M, Allison K, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11): 1364–1382.
- Mann RM, Balleyguier C, Baltzer PA, et al. European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015; 25(12): 3669–3678.
- Sardanelli F, Fallenberg EM, Clauser P, et al. European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition. Mammography: an update of the EUSOBI recommendations on information for women. Insights Imaging. 2017; 8(1): 11–18.
- Dlaczego się nie badamy? Profilaktyka nowotworowa Polek i Polaków Raport Sarcoma. Stowarzyszenie Pomocy Chorym na Mięsaki i Czerniaki Sarcoma 2022.
- https://www.nfz-szczecin.pl/hxavi_wczesne_wykrywanie_raka_piersi.htm (15.01.2023).
- https://www.nfz.gov.pl/dla-pacjenta/programy-profilaktyczne/dane-o-realizacji-programow/ (15.01.2023).
- Ostrowska A. Profilaktyka raka szyjki macicy i raka piersi: Wiedza, postawy i zachowania kobiet. Wybrane wyniki badań. Instytut Filozofii i Socjologii PAN, Warszawa 2010.
- Padoan M, Ferrante D, Pretti G, et al. Study of socio-economic characteristics, diagnosis and outcome of women participating or not participating in mammogram screening. Ann Ig. 2014; 26(6): 518–526.
- Garwacka-Czachor E, Maciejczyk A, Bębenek M. Profil społeczno-demograficzny kobiet biorących udział w skriningu mammograficznym na Dolnym Śląsku. Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY. 2017; 2(2): 119–126.
- Koper A, Kalisz Z, Mierzwa T. et.al. Znaczenie profilaktyki raka piersi w opinii kobiet wiejskich w woj. kujawsko- pomorskim. Probl Hig Epidemiol. 2010; 91(Supl. 1): 54–55.
- Dyzmann-Sroka A, Trojanowski M. Dlaczego Polki nie robią badań profilaktycznych? Nowiny Lekarskie. 2012; 81(3): 258–264.
- Perry N, Broeders M, de Wolf C. European guidelines for quality assurance in breast cancer screening and diagnosis; fourth edition. European Comission, Belgia 2006: 3–49.
- Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8(9): 784–796.
- Dyzmann-Sroka A, Jędrzejczak A, Kubiak A, et al. Wiedza o nowotworach i profilaktyce. Raport dla województwa wielkopolskiego. Wielkopolskie Centrum Onkologii, Poznań 2008: 3–34.
- Wronkowski Z, Zwierko M, Nowacki M. Zasady i wyniki programu modelowego skryningu raka piersi i raka szyjki macicy w Polsce, 1999-2000. Nowotwory, Warszawa 2002: 1–157.
- SMG/KRC – Instytut Millward Brown „Postawy wobec programu profilaktyki raka piersi” 2015.
- Smith SM, Ford JS, Rakowski W, et al. Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. Cancer Causes Control. 2010; 21(10): 1585–1595.
- Klint A, Engholm G, Storm HH, et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010; 49(5): 578–607.
- Kozierkiewicz A, Bochenek T, Gilewski D, et al. Biała Księga. Zwalczanie raka jelita grubego i raka piersi w Polsce na tle wybranych krajów europejskich. Prognozy zapadalności na raka piersi. Ośrodek Analiz Uniwersyteckich, Polskie Towarzystwo Onkologiczne, Warszawa–Kraków 2011.
- Storm HH, Engholm G, Hakulinen T, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010; 49(5): 532–544.
- https://www.acpjournals.org/doi/abs/10.7326/AITC201606070 (15.01.2023).